VCYT Technical Analysis & Stock Price Forecast
The technical analysis for Veracyte Inc (VCYT) indicates a "Strong Sell" consensus, based on an aggregation of 10 technical signals as of April 2, 2026. Key indicators like MACD and several moving averages suggest bearish sentiment, despite the Relative Strength Index (RSI) showing a neutral condition. The stock is currently trading below its 200-day simple moving average, reinforcing a long-term bearish outlook for VCYT.
Veracyte (NASDAQ:VCYT) Given "Buy" Rating at Needham & Company LLC
Needham & Company LLC has reiterated a "Buy" rating for Veracyte (NASDAQ:VCYT), setting a target price of $48.00, which suggests a 49.02% upside. This follows Veracyte's strong Q4 performance, where it exceeded EPS and revenue estimates. Despite some recent insider selling, the company's stock has garnered a consensus "Hold" rating from analysts with an average target price of $44.20.
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $48
Needham has reiterated its Buy rating for Veracyte (VCYT.US) and maintained a target price of $48. This indicates the firm's continued confidence in the company's stock performance and future prospects. Investors may view this as a positive signal for Veracyte's valuation.
Needham reiterates Veracyte stock rating on bladder cancer test plans
Needham has reiterated a Buy rating and a $48.00 price target for Veracyte (NASDAQ:VCYT), citing the company's plans to enter the minimal residual disease market with its TrueMRD platform for muscle invasive bladder cancer in the first half of 2026. The research firm believes TrueMRD, a whole genome sequencing assay, will be competitive in the highly underpenetrated $15 billion minimal residual disease market, estimating a $200 million opportunity for bladder cancer, split between TrueMRD and the existing Decipher Bladder test. Veracyte's strong financial health and recent positive earnings further support this optimistic outlook.
Cathie Wood’s ARK buys OpenAI Group stock, sells Veracyte shares
Cathie Wood's ARK ETFs made significant portfolio adjustments on March 31, 2026, selling over 115,000 shares of Veracyte Inc. for more than $3.5 million. Simultaneously, ARK invested heavily in the artificial intelligence sector by purchasing nearly 350,000 shares of OpenAI Group PBC across multiple ETFs. The firm also increased holdings in CoreWeave Inc. and DoorDash Inc. while divesting from Strata Critical Medical Inc. and Teradyne Inc.
Is Veracyte Stock a Smart Addition to Your Investment Portfolio at This Time?
Veracyte (VCYT) shows potential for growth due to strong sales of its Afirma and Decipher Prostate tests and a solid financial position, despite facing macroeconomic pressures and intense competition. While the stock has outperformed its industry, it trails the S&P 500, with analysts projecting increased earnings and revenue for 2026. The article suggests evaluating Veracyte alongside other top-ranked medical sector stocks like Globus Medical, Envista, and Intuitive Surgical.
Is Veracyte Stock the Right Pick for Your Portfolio Now?
Veracyte (VCYT) is poised for growth due to strong sales momentum in its Afirma and Decipher Prostate tests, with its research-use-only Afirma GRID offering gaining traction and the company maintaining a solid financial position. Despite macroeconomic and competitive headwinds, Veracyte has consistently topped earnings estimates, and its Afirma and Decipher franchises continue to demonstrate impressive volume growth and clinical utility. The company is actively working to reduce costs and expand test availability while navigating challenges like inflation and fierce market rivalry.
Veracyte price target lowered to $45 from $50 at Guggenheim
Guggenheim has reduced its price target for Veracyte (VCYT) shares to $45 from $50, while maintaining a Buy rating. This adjustment follows Guggenheim's review of its diagnostics and life science tools coverage, incorporating recent updates and management meetings from various companies. The firm’s models and forecasts for Veracyte were updated to reflect these changes.
Veracyte (NASDAQ:VCYT) Price Target Lowered to $45.00 at Guggenheim
Guggenheim has lowered its price target for Veracyte (NASDAQ:VCYT) to $45.00 from $50.00, while maintaining a "buy" rating, indicating a potential upside of 48.56%. The biotechnology company currently holds a "Hold" consensus rating from analysts with an average price target of $44.20. Insider transactions show top executives recently sold shares, reducing overall insider ownership to 1.40%.
Guggenheim Maintains Veracyte(VCYT.US) With Buy Rating, Cuts Target Price to $45
Guggenheim has reiterated its Buy rating on Veracyte (VCYT.US) but has reduced the target price from $50 to $45. This adjustment reflects an updated outlook from the analytical firm while still recommending investment in the company.
Veracyte (VCYT) down 15.4% since last earnings report: Can it rebound?
This article from MSN discusses Veracyte (VCYT) and its 15.4% stock decline since its last earnings report. It speculates on the possibility of a rebound for the company.
VCYT SEC Filings - Veracyte 10-K, 10-Q, 8-K Forms
This page provides access to Veracyte (VCYT) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms, with AI-powered summaries. It details recent insider transactions by Director Robert S. Epstein, an unnamed officer, SVP Annie McGuire, and CEO Marc Stapley involving stock sales and tax-related share withholdings. The platform offers a comprehensive resource for investors to track Veracyte's financial reporting and governance activities.
Veracyte (VCYT) down 15.4% since last earnings report: Can it rebound?
This article discusses Veracyte (VCYT) stock performance, noting a 15.4% decline since its last earnings report. It highlights upcoming earnings release expectations and briefly touches on key financial metrics like earnings per share (EPS) and revenue. Investors are encouraged to monitor these factors for potential future rebound indications.
Does Veracyte (NASDAQ:VCYT) Deserve A Spot On Your Watchlist?
This article examines Veracyte (NASDAQ:VCYT) as a potential investment by analyzing its financial performance, including its return on capital employed (ROCE) and capital allocation. It highlights the company's declining ROCE and the negative impact of high debt levels on its financial health, suggesting caution for investors.
Vanguard disaggregates reporting; lists zero holdings in Veracyte (VCYT)
The Vanguard Group has filed an amendment to its Schedule 13G/A for Veracyte Inc. (VCYT), reporting 0 shares beneficially owned due to an internal realignment. This change indicates that certain Vanguard subsidiaries will now report their holdings separately, in reliance on SEC Release No. 34-39538, rather than a market sale. The filing clarifies that Vanguard no longer is deemed to beneficially own securities held by these disaggregated subsidiaries.
VCYT SEC Filings - Veracyte 10-K, 10-Q, 8-K Forms
This page provides access to Veracyte (VCYT) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. It highlights the company's activities in cancer diagnostics and genomic testing and offers AI-powered summaries of these regulatory documents for investors. The article also details recent insider transactions and Q3 2025 financial results.
Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?
Veracyte (VCYT) has seen its shares drop 15.4% since its last earnings report, underperforming the S&P 500. The company reported strong Q4 2025 earnings, beating estimates for both earnings per share and revenues, and reaffirmed its 2026 guidance. Despite the recent stock decline, Veracyte holds a Zacks Rank #3 (Hold) and a strong Growth Score of A.
Veracyte, Inc. $VCYT Shares Sold by Nordea Investment Management AB
Nordea Investment Management AB reduced its stake in Veracyte, Inc. (NASDAQ:VCYT) by 12.8% in Q4 2025, selling 34,882 shares. Company insiders also sold a significant number of shares recently, totaling 75,782 shares within the last 90 days. Despite this, Veracyte beat Q4 earnings expectations with an EPS of $0.53 and revenue of $140.6 million, and analysts currently hold an average "Hold" rating with a target price of $45.20.
Veracyte (VCYT) Chief Dev and Tech Officer files initial Form 3
Veracyte (VCYT) Chief Development and Technology Officer, Kevin Richard Haas, has filed an initial Form 3 with the SEC, establishing his status as a reporting insider. This filing simply confirms his reporting obligation and does not indicate any stock transactions such as buys or sells. The document provides details of his position and the company's information.
Veracyte, Inc. (NASDAQ:VCYT) Given Average Recommendation of "Hold" by Brokerages
Veracyte, Inc. (NASDAQ:VCYT) has received an average "Hold" recommendation from brokerages, with an average 12-month price target of $45.17. The company recently reported strong Q4 earnings, surpassing analyst expectations with $0.53 EPS and $140.6 million in revenue. Despite this, there has been notable insider selling by the CEO and SVP, totaling over $2.7 million in the last 90 days.
Veracyte Taps Kevin Haas To Guide AI Push And Undervalued Shares
Veracyte (VCYT) has appointed Kevin Haas, Ph.D., as Chief Development and Technology Officer, a new role focusing on AI, software, and informatics to enhance its whole genome MRD and multi-omics initiatives. This move comes as the company's shares are trading below analyst targets and estimated fair value, despite a recent short-term decline. Haas's appointment is expected to guide Veracyte's technology integration and product development in these key areas.
Westview Management dba Westview Investment Advisors Invests $1.38 Million in Veracyte, Inc. $VCYT
Westview Management dba Westview Investment Advisors recently invested $1.38 million in Veracyte, Inc. by acquiring 32,690 shares during the fourth quarter. Despite this new institutional position and Veracyte beating Q4 earnings estimates, the stock is trading lower, and analysts have a "Hold" rating with a consensus price target of $45.17. Meanwhile, company insiders have been net sellers, disposing of shares worth approximately $2.72 million over the past three months.
Does Veracyte (VCYT) offer both strength and opportunity?
This article analyzes Veracyte (VCYT), focusing on its potential strengths and opportunities. It suggests that investors evaluate the company's financial performance and market position to determine if it presents a viable investment opportunity. The piece implies a need for a deeper dive into the company's fundamentals.
Does Veracyte (VCYT) offer both strength and opportunity?
This article analyzes Veracyte (VCYT), focusing on its potential strengths and opportunities. Without further content, specific details about its financial performance, market position, or future prospects are not available. The title suggests an evaluation of the company's current standing and growth potential.
Veracyte appoints Kevin Haas as chief development officer
Veracyte Inc. (NASDAQ: VCYT) has appointed Kevin Haas as Chief Development and Technology Officer, effective March 24, a move aimed at enhancing the company's product development and expansion into whole-genome minimal residual disease and multi-omics applications. Haas brings over 15 years of life sciences experience, including leadership roles at Myriad Genetics and Counsyl. This development follows strong financial results for Veracyte in Q4 2025, although analyst opinions on its future performance are varied.
Veracyte (NASDAQ: VCYT) hires Kevin Haas as Chief Development and Technology Officer
Veracyte, Inc. (NASDAQ: VCYT) has appointed Dr. Kevin Haas as its Chief Development and Technology Officer, effective March 24, 2026. Dr. Haas, formerly of Myriad Genetics, will receive an annual base salary of $500,000, an annual performance-based cash bonus targeted at 55% of his earnings, and equity awards totaling $3,000,000 in target value. This announcement was made via an 8-K SEC filing, indicating a moderate impact and neutral sentiment.
How Veracyte’s New AI-Focused CTO Role At Veracyte (VCYT) Has Changed Its Investment Story
Veracyte (VCYT) has appointed Kevin Haas as its first Chief Development and Technology Officer, a role focused on integrating AI, software, and genomics across its product development. This move supports Veracyte's strategy to expand beyond existing genomic tests into new platforms like whole-genome minimal residual disease (MRD), particularly for bladder cancer, with a planned launch in H1 2026. The appointment could positively influence Veracyte's long-term outlook by industrializing its platforms, although near-term challenges around reimbursement and successful MRD launch timing remain.
How Veracyte’s New AI-Focused CTO Role At Veracyte (VCYT) Has Changed Its Investment Story
Veracyte (VCYT) recently appointed Kevin Haas, Ph.D., as its first Chief Development and Technology Officer, a role emphasizing the integration of AI, software, and genomics across its product development. This strategic move aims to support the company's expanding global portfolio and its advancement into whole-genome minimal residual disease and multi-omics applications. The appointment is seen as directionally supportive of Veracyte's investment narrative, particularly concerning its upcoming whole genome MRD platform launch, although near-term focus remains on launch timing and reimbursement risks.
Veracyte appoints Kevin Haas as chief development officer By Investing.com
Veracyte Inc. (NASDAQ:VCYT) has appointed Kevin Haas as Chief Development and Technology Officer, effective March 24. Haas, with over 15 years of life sciences industry experience, will oversee product development, including diagnostic assay development and bioinformatics, to support the company's expansion into whole-genome minimal residual disease and multi-omics applications. This announcement follows recent financial results where Veracyte exceeded analyst expectations for Q4 2025.
Veracyte, Inc. Appoints Kevin Haas as Chief Development and Technology Officer, Effective March 24, 2026
Veracyte, Inc. has announced the appointment of Kevin Haas, Ph.D., as its Chief Development and Technology Officer, effective March 24, 2026. In this new role, Dr. Haas will lead the company's global product development strategy, overseeing diagnostic assay development, software, bioinformatics, and the product development program office. His expertise in automated lab technology and AI systems from his previous role at Myriad Genetics will be crucial as Veracyte expands into whole-genome minimal residual disease (MRD) and multi-omics applications.
Veracyte Appoints Kevin Haas as Chief Technology Leader
Veracyte (VCYT) has appointed Dr. Kevin Haas as Chief Development and Technology Officer, effective March 24, 2026. This strategic hire aims to enhance Veracyte's technological and product development capabilities in the precision diagnostics market. Dr. Haas's compensation includes a $500,000 base salary, bonus eligibility, and substantial equity awards, aligning his incentives with the company's long-term success.
Veracyte Names Kevin Haas as Chief Development and Technology Officer
Veracyte, Inc. (Nasdaq: VCYT) has appointed Kevin Haas, Ph.D., as its new Chief Development and Technology Officer. This new role will focus on advancing and scaling the company's global product development strategy, encompassing diagnostic assays, software, and bioinformatics, especially as Veracyte expands into whole-genome minimal residual disease and other multi-omics applications. Dr. Haas brings over 15 years of experience in life sciences technology, research, and development, previously serving as Chief Technology Officer at Myriad Genetics.
Iron Triangle Partners LP Purchases New Position in Veracyte, Inc. $VCYT
Iron Triangle Partners LP has acquired a new position in Veracyte, Inc. ($VCYT), purchasing 485,000 shares valued at approximately $16.65 million. This investment makes Veracyte the fund's 21st largest holding, representing about 2.4% of its portfolio. Despite recent insider selling, with 86,521 shares offloaded by company insiders, Veracyte reported better-than-expected earnings for the latest quarter.
Fred Alger Management LLC Takes $26.35 Million Position in Veracyte, Inc. $VCYT
Fred Alger Management LLC has acquired a new stake in Veracyte, Inc. (NASDAQ:VCYT), purchasing 767,479 shares valued at approximately $26.35 million. This investment makes Fred Alger Management LLC a major holder, owning 0.97% of Veracyte. The move follows Veracyte's strong quarterly performance, where it exceeded earnings estimates and reported an 18.5% year-over-year revenue increase, despite some recent insider stock sales.
Bamco Inc. NY Decreases Stake in Veracyte, Inc. $VCYT
Bamco Inc. NY significantly reduced its stake in Veracyte, Inc. (NASDAQ:VCYT) by 26.4% in the Q3, selling over 231,000 shares, though it still holds 0.82% of the company worth $22.16 million. Veracyte reported better-than-expected Q3 earnings with $0.53 EPS and $140.64 million in revenue, an 18.5% year-over-year increase. Despite mixed analyst ratings, the average target price for Veracyte is $45.14, and there have been recent insider share sales by company executives.
Veracyte, Inc. $VCYT is ArrowMark Colorado Holdings LLC's 7th Largest Position
ArrowMark Colorado Holdings LLC has retained Veracyte, Inc. (VCYT) as its 7th largest position, despite a slight reduction of 1.3% in its stake, now owning 2,545,739 shares worth approximately $87.4 million. The article also highlights insider selling by Veracyte's CEO and CFO, who collectively sold shares valued at over $2 million, reducing their holdings by about 11-12%. Veracyte recently surpassed earnings estimates, reporting an EPS of $0.53 and revenue of $140.6 million, marking an 18.5% year-over-year increase, and analysts maintain a "Hold" rating with an average price target of $45.14.
Veracyte Inc Stock (ISIN: US92347M1009) Holds Steady Amid Analyst Downgrade and Mixed Signals
Veracyte Inc (VCYT) stock is trading around $27.51 after a downgrade from Zacks Research to "Hold" from "Strong Buy," despite reporting robust revenue growth in 2024. The company, a leader in cancer diagnostics, shows caution regarding short-term catalysts while maintaining strong Value, Growth, and Momentum scores. European investors are monitoring its performance, particularly given increasing demand for oncology tests and the company's focus on high-margin genomic diagnostics.
Veracyte (VCYT) CAO awarded 10,525 RSUs in new equity grant
Jonathan Wygant, VP and Chief Accounting Officer of Veracyte (VCYT), was granted 10,525 restricted stock units on March 6, 2026, as part of his compensation. These units will vest 25% on March 2, 2027, with the remainder vesting quarterly thereafter, contingent on his continued employment. Following this award, Wygant directly holds 45,434 shares of Veracyte common stock.
Veracyte (VCYT) grants CEO Marc Stapley 92,099 RSUs vesting from 2027
Veracyte (VCYT) CEO Marc Stapley was granted 92,099 restricted stock units (RSUs) on March 6, 2026. These RSUs will vest 25% on March 2, 2027, with the remainder vesting quarterly thereafter, contingent on his continued employment. Following this award, Stapley directly holds 449,653 shares of the company, reflecting equity compensation rather than a market purchase.
Veracyte, Inc. (NASDAQ:VCYT) Q2 2025 Earnings Call Transcript
This is an earnings call transcript for Veracyte, Inc. (NASDAQ:VCYT) for the second quarter of 2025. The document contains a detailed report of the company's financial performance and related discussions during the call.
Are Veracyte's (VCYT) Strong 2025 Profits and Reaffirmed 2026 Outlook Redefining Its Growth Story?
Veracyte (VCYT) reported strong financial results for Q4 and full-year 2025, exceeding previous year's earnings per share and reaching substantial revenue and net income figures. The company also reaffirmed its 2026 revenue growth outlook of 10% to 13%, indicating management's continued confidence in demand for its genomic tests. While this supports the near-term growth narrative, potential long-term risks such as reimbursement pressures and competition in AI-enabled diagnostics remain factors for investors to consider.
Are Veracyte's (VCYT) Strong 2025 Profits and Reaffirmed 2026 Outlook Redefining Its Growth Story?
Veracyte Inc. reported strong financial results for Q4 and full-year 2025, with increased revenue and net income, and reaffirmed its 2026 revenue growth outlook of 10% to 13%. This performance suggests management's confidence in continued testing demand for its genomic tests like Decipher and Afirma. While these results support near-term growth, the article notes that investors should remain watchful of potential reimbursement scrutiny and competition in the AI-enabled diagnostics market, which could impact future margins.
Insider Sell: Rebecca Chambers Sells Shares of Veracyte Inc (VCY)
Rebecca Chambers, CFO of Veracyte Inc (VCYT), sold 18,341 shares of the company on March 4, 2026. This transaction brings her total sales over the past year to 38,619 shares, with no purchases. Veracyte Inc is a genomic diagnostics company, and the stock is currently deemed fairly valued based on its GF Value.
Veracyte (NASDAQ:VCYT) CFO Rebecca Chambers Sells 18,341 Shares
Veracyte (NASDAQ:VCYT) CFO Rebecca Chambers sold 18,341 shares of the company's stock on March 4th for a total of $662,843.74, reducing her holding by 12.27%. This sale was disclosed after Veracyte reported strong quarterly earnings, beating analyst expectations for both EPS and revenue. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $45.14.
Veracyte (NASDAQ:VCYT) Insider Sells 5,260 Shares
Veracyte (NASDAQ:VCYT) insider John Leite sold 5,260 shares of the company's stock on March 4, 2026, for a total of $185,099.40. This sale reduced his position by 4.66% to 107,580 shares. The company recently reported strong quarterly earnings, beating analyst estimates with $0.53 EPS and $140.6 million in revenue.
Marc Stapley Sells 45,523 Shares of Veracyte (NASDAQ:VCYT) Stock
Veracyte CEO Marc Stapley sold 45,523 shares of the company's stock on March 4th for approximately $1.64 million, reducing his stake by 11.29%. This sale occurred shortly after Veracyte reported stronger-than-expected Q4 earnings, beating consensus estimates with $0.53 EPS and $140.64 million in revenue. Despite mixed analyst ratings, the stock currently holds a "Moderate Buy" consensus with an average target price of $45.14.
Veracyte (NASDAQ:VCYT) SVP Annie Mcguire Sells 6,658 Shares
Veracyte's SVP, Annie Mcguire, sold 6,658 shares of VCYT stock on March 4th for $236,691.90, reducing her stake by 6.57%. This follows a previous sale of 10,739 shares in December. The company recently reported better-than-expected earnings with an EPS of $0.53 and revenue of $140.64 million, despite mixed analyst sentiment, with a consensus "Moderate Buy" rating.
Morgan Stanley cuts Veracyte stock price target on valuation methodology
Morgan Stanley has lowered its price target for Veracyte (NASDAQ:VCYT) from $48 to $37, maintaining an Underweight rating. This adjustment is primarily due to a change in their valuation methodology, specifically a higher WACC derived from a three-year levered adjusted beta. Despite this, Veracyte recently reported strong Q4 2025 results, surpassing analyst expectations for EPS and revenue, leading Needham to raise its price target to $48.
Morgan Stanley Lowers Price Target on Veracyte to $37 From $48, Keeps Underweight Rating
Morgan Stanley has revised its price target for Veracyte (VCYT) shares down to $37 from $48, while maintaining an Underweight rating on the stock. This adjustment reflects a more cautious outlook from the investment bank for the biotechnology and medical research company. The update follows recent insider share sales reported by Veracyte executives.
Morgan Stanley cuts Veracyte stock price target on valuation methodology By Investing.com
Morgan Stanley reduced its price target for Veracyte, Inc. (NASDAQ:VCYT) to $37 from $48, maintaining an Underweight rating, primarily due to a change in its valuation methodology, specifically a higher WACC derived from a three-year levered adjusted beta. This contrasts with broader Wall Street sentiment, where the consensus target is $53, and follows Veracyte's strong fourth-quarter 2025 financial results which surpassed analyst expectations. Needham also recently raised its price target for Veracyte to $48.
